Cormedix Inc (CRMD)

$8.12 -0.05 (-0.61%)
Market Cap 611.40M
Revenue (ttm) 43.47M
Net Income (ttm) -17.93M
EPS (ttm) N/A
PE Ratio 5.85
Forward PE 6.38
Profit Margin -41.25%
Debt to Equity Ratio 0.00
Volume 1,583,400
Avg Vol 3,264,378
Day's Range N/A - N/A
Shares Out 78.79M
Stochastic %K 70%
Beta 1.36
Analysts Strong Sell
Price Target $15.43

Company Profile

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was in...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 517 9500
Fax: 908 375 8272
Address:
300 Connell Drive, Suite 4200, Berkeley Heights, United States
Noname2022
Noname2022 Feb. 4 at 4:34 AM
$CRMD
1 · Reply
Noname2022
Noname2022 Feb. 4 at 12:08 AM
$CRMD
0 · Reply
Gencooliveoil
Gencooliveoil Feb. 3 at 11:00 PM
$CRMD Institutional Ownership Highlights (As of Early 2026): Top Holders: BlackRock, Inc. (approx. 7.5% stake), Vanguard Group Inc, Marshall Wace, LLP, and Deerfield Management are among the largest institutional shareholders. Recent Buying Activity: Substantial recent increases in positions were noted from Marshall Wace, Alyeska Investment Group, and Deerfield Management, while BlackRock increased its holdings by over 30% in early 2025. Total Institutional Holdings: Approximately 316 institutions hold over 49 million shares. Company Buyback: In February 2026, CorMedix announced its board approved a $75 million share-repurchase program, set to begin in Q1 2026, indicating confidence in the stock's valuation. Fintel +3
0 · Reply
Noname2022
Noname2022 Feb. 3 at 10:57 PM
$CRMD $FMS “focusing on where we can have the most impact: quality and patient safety”
0 · Reply
golfguy42360
golfguy42360 Feb. 3 at 10:40 PM
$CRMD Said it before I'll say it again don't give a shit what news they put out.Not going anywhere until the shorts leave when that happens I'm loading up.
0 · Reply
Shibby_Boss
Shibby_Boss Feb. 3 at 10:12 PM
$CRMD to me, its very strongly points to a strategic hit piece targetting growth of sales and therefor asset value (stock price) by management for the RSUs and possibly the sharebuy back. Always risk but I assume they will come out with some form of news in the next few months to reverse that message.
1 · Reply
GardeningGirl
GardeningGirl Feb. 3 at 9:52 PM
$CRMD
1 · Reply
Gencooliveoil
Gencooliveoil Feb. 3 at 9:16 PM
$CRMD CorMedix (NasdaqGM:CRMD) is hosting an analyst day focused on its late stage clinical programs. The event will feature updates on REZZAYO for fungal infection prophylaxis and DefenCath for catheter related bloodstream infection prevention. Management is expected to outline current program status and broader business direction for these key assets. For investors watching CorMedix, the focus is on how these late stage assets fit into the broader infection prevention space. REZZAYO and DefenCath target serious complications linked to invasive treatments, an area that continues to draw attention as hospitals and regulators focus on patient safety and healthcare associated infections. This analyst day is important because it could clarify how CorMedix plans to position, prioritize, and resource its pipeline. Investors may be looking for specific information on timelines, regulatory interactions, and commercial planning to better understand how the company is approaching its next phase.
1 · Reply
btdb
btdb Feb. 3 at 9:14 PM
$CRMD crazy end of day trading. 20% of today’s volume in the last 12 minutes more or less. Volume down 50% today to 1.5mm shares and hence 12 days to cover. I can’t make sense out of the short case anymore. Even the convertible arbitrage loses its appeal with volume dropping. The algos fighting it out in the last few minutes was instructive on how few shares it takes to run this down, but overall, the numbers don’t seem to work unless tutes are willing to sell under 11. 50 million institutional shares held, 5,5 million by insiders, over the course of a year perhaps close to 10 million shares for buybacks and under 80million share float with 18 million shares short and today’s volume around 1.5 million. Can anyone make sense of where the shorts get 18 million shares to cover? They can borrow from large institutions (Vanguard for example loans shares, typically).
1 · Reply
Gencooliveoil
Gencooliveoil Feb. 3 at 9:12 PM
$CRMD Very strategic move to flush out short positions creating a "floor" for the stock price or drive it higher, forcing short sellers to cover at a loss.
1 · Reply
Latest News on CRMD
CorMedix Therapeutics Announces Share Repurchase Program

Feb 2, 2026, 8:30 AM EST - 1 day ago

CorMedix Therapeutics Announces Share Repurchase Program

CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026

Jan 29, 2026, 8:30 AM EST - 5 days ago

CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026

CorMedix Inc. (CRMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 1:26 AM EST - 21 days ago

CorMedix Inc. (CRMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 8:30 AM EST - 25 days ago

CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Why is CorMedix stock crashing today: is it worth buying on the dip?

Jan 8, 2026, 1:37 PM EST - 26 days ago

Why is CorMedix stock crashing today: is it worth buying on the dip?

CorMedix Therapeutics Announces Leadership and Board Updates

Jan 8, 2026, 8:05 AM EST - 26 days ago

CorMedix Therapeutics Announces Leadership and Board Updates

CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates

Jan 8, 2026, 8:00 AM EST - 26 days ago

CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates

CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath

Dec 18, 2025, 8:00 AM EST - 6 weeks ago

CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath

CorMedix: Raised Guidance, NOL Confidence, And Rezzayo Optionality Justify A Hold Rating

Nov 14, 2025, 2:56 PM EST - 2 months ago

CorMedix: Raised Guidance, NOL Confidence, And Rezzayo Optionality Justify A Hold Rating

Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:05 PM EST - 2 months ago

Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

TLPH

CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations

Nov 12, 2025, 11:49 AM EST - 2 months ago

CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations

CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 11:11 AM EST - 2 months ago

CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript

CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance

Nov 12, 2025, 7:30 AM EST - 2 months ago

CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance

CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025

Oct 31, 2025, 8:30 AM EDT - 3 months ago

CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025

CorMedix: Strong Buy After Strong Developments And A Strategy Before Earnings

Oct 23, 2025, 11:29 PM EDT - 3 months ago

CorMedix: Strong Buy After Strong Developments And A Strategy Before Earnings

CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath

Oct 23, 2025, 8:30 AM EDT - 3 months ago

CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath

Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 22, 2025, 4:05 PM EDT - 3 months ago

Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their Rights

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

Oct 20, 2025, 9:42 AM EDT - 3 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CELC RANI RAPT

CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance

Oct 20, 2025, 7:30 AM EDT - 3 months ago

CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance

CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO

Sep 29, 2025, 8:30 AM EDT - 4 months ago

CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO

CorMedix: Strong Adoption Curve And Policy Environment

Sep 22, 2025, 4:46 AM EDT - 4 months ago

CorMedix: Strong Adoption Curve And Policy Environment

CorMedix Inc. (CRMD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 1:18 PM EDT - 5 months ago

CorMedix Inc. (CRMD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

CorMedix Announces Strategic Minority Investment in Talphera

Sep 8, 2025, 8:30 AM EDT - 5 months ago

CorMedix Announces Strategic Minority Investment in Talphera

TLPH

Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market

Sep 8, 2025, 8:30 AM EDT - 5 months ago

Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market

TLPH

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team

Sep 2, 2025, 7:30 AM EDT - 5 months ago

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team

CorMedix to Participate in Upcoming Investor Conferences

Aug 28, 2025, 8:30 AM EDT - 5 months ago

CorMedix to Participate in Upcoming Investor Conferences

CorMedix: The Undervalued Breakthrough

Aug 26, 2025, 2:41 AM EDT - 5 months ago

CorMedix: The Undervalued Breakthrough

CorMedix, Inc. (CRMD) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 3:16 PM EDT - 6 months ago

CorMedix, Inc. (CRMD) Q2 2025 Earnings Call Transcript

CorMedix to Buy Melinta Therapeutics for $300 Million

Aug 7, 2025, 10:49 AM EDT - 6 months ago

CorMedix to Buy Melinta Therapeutics for $300 Million

Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership

Aug 7, 2025, 7:10 AM EDT - 6 months ago

Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership

CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

Aug 7, 2025, 7:00 AM EDT - 6 months ago

CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 7:00 AM EDT - 6 months ago

Cormedix Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update

CorMedix Analyst Says Investors Could Be Further Rewarded

Jun 30, 2025, 2:24 PM EDT - 7 months ago

CorMedix Analyst Says Investors Could Be Further Rewarded

CorMedix Seems Significantly Undervalued

Jun 30, 2025, 2:14 PM EDT - 7 months ago

CorMedix Seems Significantly Undervalued

Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Jun 27, 2025, 9:09 AM EDT - 7 months ago

Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session

CNXC

CorMedix Inc. Announces Pricing of Public Offering of Common Stock

Jun 27, 2025, 8:00 AM EDT - 7 months ago

CorMedix Inc. Announces Pricing of Public Offering of Common Stock

CorMedix Inc. Announces Proposed Public Offering of Common Stock

Jun 26, 2025, 4:01 PM EDT - 7 months ago

CorMedix Inc. Announces Proposed Public Offering of Common Stock

CorMedix inc. Announces Customer Implementation

Jun 23, 2025, 7:30 AM EDT - 8 months ago

CorMedix inc. Announces Customer Implementation

CorMedix: DefenCath In Exponential Growth Phase With Robust Market Position

Jun 5, 2025, 12:37 AM EDT - 8 months ago

CorMedix: DefenCath In Exponential Growth Phase With Robust Market Position

CorMedix: Exceeding Expectations

Jun 4, 2025, 12:41 PM EDT - 8 months ago

CorMedix: Exceeding Expectations

CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference

May 30, 2025, 8:30 AM EDT - 8 months ago

CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference

CorMedix Inc. to Participate in the RBC Global Healthcare Conference

May 15, 2025, 8:30 AM EDT - 9 months ago

CorMedix Inc. to Participate in the RBC Global Healthcare Conference

CorMedix, Inc. (CRMD) Q1 2025 Earnings Call Transcript

May 6, 2025, 11:59 AM EDT - 9 months ago

CorMedix, Inc. (CRMD) Q1 2025 Earnings Call Transcript

CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 7:30 AM EDT - 9 months ago

CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

Apr 29, 2025, 8:30 AM EDT - 10 months ago

CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

Apr 8, 2025, 7:30 AM EDT - 10 months ago

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 8:30 AM EDT - 10 months ago

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

Noname2022
Noname2022 Feb. 4 at 4:34 AM
$CRMD
1 · Reply
Noname2022
Noname2022 Feb. 4 at 12:08 AM
$CRMD
0 · Reply
Gencooliveoil
Gencooliveoil Feb. 3 at 11:00 PM
$CRMD Institutional Ownership Highlights (As of Early 2026): Top Holders: BlackRock, Inc. (approx. 7.5% stake), Vanguard Group Inc, Marshall Wace, LLP, and Deerfield Management are among the largest institutional shareholders. Recent Buying Activity: Substantial recent increases in positions were noted from Marshall Wace, Alyeska Investment Group, and Deerfield Management, while BlackRock increased its holdings by over 30% in early 2025. Total Institutional Holdings: Approximately 316 institutions hold over 49 million shares. Company Buyback: In February 2026, CorMedix announced its board approved a $75 million share-repurchase program, set to begin in Q1 2026, indicating confidence in the stock's valuation. Fintel +3
0 · Reply
Noname2022
Noname2022 Feb. 3 at 10:57 PM
$CRMD $FMS “focusing on where we can have the most impact: quality and patient safety”
0 · Reply
golfguy42360
golfguy42360 Feb. 3 at 10:40 PM
$CRMD Said it before I'll say it again don't give a shit what news they put out.Not going anywhere until the shorts leave when that happens I'm loading up.
0 · Reply
Shibby_Boss
Shibby_Boss Feb. 3 at 10:12 PM
$CRMD to me, its very strongly points to a strategic hit piece targetting growth of sales and therefor asset value (stock price) by management for the RSUs and possibly the sharebuy back. Always risk but I assume they will come out with some form of news in the next few months to reverse that message.
1 · Reply
GardeningGirl
GardeningGirl Feb. 3 at 9:52 PM
$CRMD
1 · Reply
Gencooliveoil
Gencooliveoil Feb. 3 at 9:16 PM
$CRMD CorMedix (NasdaqGM:CRMD) is hosting an analyst day focused on its late stage clinical programs. The event will feature updates on REZZAYO for fungal infection prophylaxis and DefenCath for catheter related bloodstream infection prevention. Management is expected to outline current program status and broader business direction for these key assets. For investors watching CorMedix, the focus is on how these late stage assets fit into the broader infection prevention space. REZZAYO and DefenCath target serious complications linked to invasive treatments, an area that continues to draw attention as hospitals and regulators focus on patient safety and healthcare associated infections. This analyst day is important because it could clarify how CorMedix plans to position, prioritize, and resource its pipeline. Investors may be looking for specific information on timelines, regulatory interactions, and commercial planning to better understand how the company is approaching its next phase.
1 · Reply
btdb
btdb Feb. 3 at 9:14 PM
$CRMD crazy end of day trading. 20% of today’s volume in the last 12 minutes more or less. Volume down 50% today to 1.5mm shares and hence 12 days to cover. I can’t make sense out of the short case anymore. Even the convertible arbitrage loses its appeal with volume dropping. The algos fighting it out in the last few minutes was instructive on how few shares it takes to run this down, but overall, the numbers don’t seem to work unless tutes are willing to sell under 11. 50 million institutional shares held, 5,5 million by insiders, over the course of a year perhaps close to 10 million shares for buybacks and under 80million share float with 18 million shares short and today’s volume around 1.5 million. Can anyone make sense of where the shorts get 18 million shares to cover? They can borrow from large institutions (Vanguard for example loans shares, typically).
1 · Reply
Gencooliveoil
Gencooliveoil Feb. 3 at 9:12 PM
$CRMD Very strategic move to flush out short positions creating a "floor" for the stock price or drive it higher, forcing short sellers to cover at a loss.
1 · Reply
Gencooliveoil
Gencooliveoil Feb. 3 at 9:11 PM
$CRMD
1 · Reply
Miketj
Miketj Feb. 3 at 8:54 PM
$CRMD stochastic is about to signal sell 🤮
0 · Reply
Derek22us
Derek22us Feb. 3 at 8:51 PM
$CRMD Dirty Rotten disgusting manipulating bassturds.
0 · Reply
Miketj
Miketj Feb. 3 at 8:51 PM
$CRMD blah blah blah same sh!t different day. I’ll post when I see something worthy GLA
0 · Reply
btdb
btdb Feb. 3 at 8:33 PM
$CRMD this ends green today
1 · Reply
Derek22us
Derek22us Feb. 3 at 8:09 PM
$CRMD Never a shortage of little lot trading dipchits led by 700 and 1100 algo penny scavenging sheisters.
0 · Reply
wolverine
wolverine Feb. 3 at 6:58 PM
$CRMD so do the stock repurchases have to be cleared with Deerfield? You take T Th and Fr? And we’ll buy on M and W? Seems like nothing much will change with Deerfield and such a large short interest?
1 · Reply
Letthegamesbegin
Letthegamesbegin Feb. 3 at 6:31 PM
$CRMD Penny flipping POS. Get out of this stock already and go flip tech shares.🖕
0 · Reply
ZacksResearch
ZacksResearch Feb. 3 at 4:43 PM
$CRMD just approved a $75M buyback — that’s a serious confidence signal 👀 Management greenlit a share repurchase program running through December 31, 2027, citing a strong balance sheet, solid operating performance, and expected ongoing cash flow generation. With ~$150M in cash and 79.3M shares outstanding as of December 31, 2025, they’re positioning to return value while still funding growth and late-stage clinical programs. See what this move could mean for CRMD shareholders 👉 https://www.zacks.com/stock/quote/CRMD/detailed-earning-estimates?cid=sm-stocktwits-0-detailed_estimates-oc-31764&ADID=SYND_STOCKTWITS_TWEET_0_DETAILEDESTIMATES_OC_31764
1 · Reply
Brunoez
Brunoez Feb. 3 at 4:27 PM
$CRMD Great points--For any normal stock, the tea leaves would be clear. Since we're talking about CRMD, however, I wouldn't put it past Joe to rebuy the 6.6M shares he sold at $13 last June on the cheap, then turn around and re-issue them at a higher price when he's ready to pull the trigger on TLPH.
0 · Reply
firedupinvestors
firedupinvestors Feb. 3 at 4:18 PM
$CRMD but still....we are more than 50% off the 52 week high. That was one massive dump.
0 · Reply
Oct
Oct Feb. 3 at 4:12 PM
$CRMD Smiling quietly.... could the buyback and the funding for it be another of Joey's misdirection moves... possibly allocating it to protect the $5 threshold if it is needed as some Institutions, not all, would be required to sell if the sp got pushed down there by Deerfield and friends........ could Deerfield be looking at Crmd as Melinta #2? Maybe Joe is beginning to realize he is swimming in an area filled with sharks...
0 · Reply